Documentación Coronavirus

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY.
BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
PMID: 35236664​

Although myocarditis and pericarditis were not observed as adverse events in coronavirus disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population. 

Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, Cremona G, Muroni M, Bernuzzi P, Lo Cascio G, Schiavo R, Mutti M, Tassi M, Mariano M, Trubini S, Bandieramonte G, Maestri R, Mordenti P, Marazzi E, Vallisa D.

Eur J Cancer. 2021 Nov;157:441-449. doi: 10.1016/j.ejca.2021.08.035. Epub 2021 Sep 2.
PMID: 34601285​

Fu C, Stoeckle JH, Masri L, Pandey A, Cao M, Littman D, Rybstein M, Saith SE, Yarta K, Rohatgi A, Makarov DV, Sherman SE, Morrissey C, Jordan AC, Razzo B, Theprungsirikul P, Tsai J, Becker DJ.Cancer. 2021 Sep 15;127(18):3466-3475. doi: 10.1002/cncr.33657. Epub 2021 Jun 7.PMID: 34096048

Russo D, Polverelli N, Malagola M, Farina M, Leoni A, Bernardi S, Mammoliti S, Sacchi N, Martino M, Ciceri F; GITMO Centers. Bone Marrow Transplant. 2021 Sep;56(9):2272-2275. doi: 10.1038/s41409-021-01287-w. Epub 2021 Apr 19.PMID: 33875810

Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, Sang-Soo Lee Front Immunol. 2021; 12: 679344. doi: 10.3389/fimmu.2021.679344

Anne-Gaëlle Goubet, Agathe Dubuisson, Arthur Geraud, François-Xavier Danlos, Safae Terrisse, Carolina Alves Costa Silva, Damien Drubay, Lea Touri, Marion Picard, Marine Mazzenga, Aymeric Silvin, Garett Dunsmore, Yacine Haddad, Eugenie Pizzato, Pierre Ly, Caroline Flament, Cléa Melenotte, Eric Solary, Michaela Fontenay, Gabriel Garcia, Corinne Balleyguier, Nathalie Lassau, Markus Maeurer, Claudia Grajeda-Iglesias, Nitharsshini Nirmalathasan, Fanny Aprahamian, Sylvère Durand, Oliver Kepp, Gladys Ferrere, Cassandra Thelemaque, Imran Lahmar, Jean-Eudes Fahrner, Lydia Meziani, Abdelhakim Ahmed-Belkacem, Nadia Saïdani, Bernard La Scola, Didier Raoult, Stéphanie Gentile, Sébastien Cortaredona, Giuseppe Ippolito, Benjamin Lelouvier, Alain Roulet, Fabrice Andre, Fabrice Barlesi, Jean-Charles Soria, Caroline Pradon, Emmanuelle Gallois, Fanny Pommeret, Emeline Colomba, Florent Ginhoux, Suzanne Kazandjian, Arielle Elkrief, Bertrand Routy, Makoto Miyara, Guy Gorochov, Eric Deutsch, Laurence Albiges, Annabelle Stoclin, Bertrand Gachot, Anne Florin, Mansouria Merad, Florian Scotte, Souad Assaad, Guido Kroemer, Jean-Yves Blay, Aurélien Marabelle, Frank Griscelli, Laurence Zitvogel, Lisa Derosa
Cell Death Differ. 2021 Jul 6 : 1–19. doi: 10.1038/s41418-021-00817-9 
 

The SARS-Cov-2 pandemic in 2020 has caused oncology teams around the world to adapt their practice in the aim of protecting patients. Early evidence from China indicated that patients with cancer, and particularly those who had recently received
chemotherapy or surgery, were at increased risk of adverse outcomes following SARS-Cov-2 infection. Many registries of cancer patients infected with SARS-Cov-2 emerged during the first wave. We collate the evidence from these national and international
studies and focus on the risk factors for patients with solid cancers and the contribution of systemic anti-cancer treatments (SACT—chemotherapy, immunotherapy, targeted and hormone therapy) to outcomes following SARS-Cov-2 infection. Patients with cancer
infected with SARS-Cov-2 have a higher probability of death compared with patients without cancer. Common risk factors for mortality following COVID-19 include age, male sex, smoking history, number of comorbidities and poor performance status.
Oncological features that may predict for worse outcomes include tumour stage, disease trajectory and lung cancer. Most studies did not identify an association between SACT and adverse outcomes. Recent data suggest that the timing of receipt of SACT may
be associated with risk of mortality. Ongoing recruitment to these registries will enable us to provide evidence-based care.

Practically every aspect of modern life has been upended by the ongoing COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV- 2) that merged in 2019. Yet, despite substantial disruptions to the day-to-day practices of caring for patients and
performing research, the biomedical community as a whole has rallied and adapted.

Through creativity, collaboration across disciplines, open communication, and a commitment
to the scientific enterprise, the amount of knowledge generated in merely 1 year on an entity that was previously unknown to humans was, to use the word-of-the-year for 2020, unprecedented.

Practically every aspect of modern life has been upended by the ongoing COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) that merged in 2019. Yet, despite substantial disruptions to the day-to-day practices of caring for patients and
performing research, the biomedical community as a whole has rallied and adapted.Through creativity, collaboration across disciplines,open communication, and a commitment to the scientific enterprise, the amountof knowledge generated in merely 1 year on an entity that was previously unknown to humans was, to use the word-of-the-year for 2020, unprecedented.

Cancer care has been profoundly impacted by the global pandemic of severe acute respiratory syndrome coronavirus 2 disease (coronavirus disease 2019, COVID-19), resulting in unprecedented challenges. Supportive care is an essential component of cancer treatment, seeking to prevent and manage chemotherapy complications such as febrile neutropenia, anaemia, thrombocytopenia/bleeding, thromboembolic events and nausea/vomiting, all of which are common causes of hospitalisation. These adverse events are an essential consideration under routine patient management, but particularly so during a pandemic, a setting in which clinicians aim to minimise patients' risk of infection and need for hospital visits. Professional medical oncology societies have been providing updated guidelines to support health care professionals with the management, treatment and supportive care needs of their patients with cancer under the threat of COVID-19. This paper aims to review the recommendations made by the most prominent medical oncology societies for devising and modifying supportive care strategies during the pandemic.

While routine, in-person follow-up of early-stage breast cancer patients (EBC) after completion of initial treatment is common, the COVID-19 pandemic has resulted in unprecedented changes in clinical practice. A systematic review was performed to evaluate the evidence supporting different frequencies of routine follow-up.